187 related articles for article (PubMed ID: 38135443)
21. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD
Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566
[TBL] [Abstract][Full Text] [Related]
22. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
23. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Smith S; Rowbotham NJ; Charbek E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008319. PubMed ID: 30376155
[TBL] [Abstract][Full Text] [Related]
24. Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum.
Serisier DJ; Carroll MP; Shute JK; Young SA
Respir Res; 2009 Jul; 10(1):63. PubMed ID: 19580650
[TBL] [Abstract][Full Text] [Related]
25. Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease.
Baines KJ; Fu JJ; McDonald VM; Gibson PG
Int J Chron Obstruct Pulmon Dis; 2017; 12():541-550. PubMed ID: 28223794
[TBL] [Abstract][Full Text] [Related]
26. Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population.
Dalal AA; Patel J; D'Souza A; Farrelly E; Nagar S; Shah M
J Manag Care Spec Pharm; 2015 Jul; 21(7):575-83. PubMed ID: 26108382
[TBL] [Abstract][Full Text] [Related]
27. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
[TBL] [Abstract][Full Text] [Related]
28. Frequent exacerbators of chronic obstructive pulmonary disease have distinguishable sputum microbiome signatures during clinical stability.
Dang X; Kang Y; Wang X; Cao W; Li M; He Y; Pan X; Ye K; Xu D
Front Microbiol; 2022; 13():1037037. PubMed ID: 36532417
[TBL] [Abstract][Full Text] [Related]
29. Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6.
Majka G; Mazurek H; Strus M; Ciszek-Lenda M; Szatanek R; Pac A; Golińska E; Marcinkiewicz J
Clin Exp Immunol; 2021 Sep; 205(3):391-405. PubMed ID: 34031873
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE; Schechter MS; Wagener JS; Morgan WJ; Pasta DJ; Elkin EP; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):649-57. PubMed ID: 22949088
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
[TBL] [Abstract][Full Text] [Related]
32. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ
J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975
[TBL] [Abstract][Full Text] [Related]
33. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
[TBL] [Abstract][Full Text] [Related]
34. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation.
Downey DG; Brockbank S; Martin SL; Ennis M; Elborn JS
Pediatr Pulmonol; 2007 Aug; 42(8):729-35. PubMed ID: 17588254
[TBL] [Abstract][Full Text] [Related]
35. Heparin-binding protein in sputum as a marker of pulmonary inflammation, lung function, and bacterial load in children with cystic fibrosis.
Hovold G; Palmcrantz V; Kahn F; Egesten A; Påhlman LI
BMC Pulm Med; 2018 Jun; 18(1):104. PubMed ID: 29925362
[TBL] [Abstract][Full Text] [Related]
36. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
[TBL] [Abstract][Full Text] [Related]
37. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
38. Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease.
Chang C; Yao W
Med Sci Monit; 2014 Feb; 20():311-20. PubMed ID: 24569299
[TBL] [Abstract][Full Text] [Related]
39. Airway iron and iron-regulatory cytokines in cystic fibrosis.
Reid DW; Lam QT; Schneider H; Walters EH
Eur Respir J; 2004 Aug; 24(2):286-91. PubMed ID: 15332399
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
